

Supplementary Material

Searching for new tools to counteract the *Helicobacter pylori* resistance: the positive action of resveratrol derivatives

Paola Di Fermo^{1#}, Silvia Di Lodovico^{1#}, Rosa Amoroso¹, Barbara De Filippis¹, Simonetta D'Ercole², Emanuela Di Campli¹, Luigina Cellini^{1*} and Mara Di Giulio¹

- ¹ Department of Pharmacy, "University "G. d'Annunzio" Chieti-Pescara, Via dei Vestini 31, 66100 Chieti (CH), Italy; paola.difermo@unich.it (P.D.F.); silvia.dilodovico@unich.it (S.D.L.); rosa.amoroso@unich.it (R.A.); barbara.defilippis@unich.it (B.D.F.); e.dicamplici@unich.it (E.D.C.); l.cellini@unich.it (L.C.); mara.digiulio@unich.it (M.D.G.)
- ² Department of Medical Oral and Biotechnological Sciences, University "G. d'Annunzio" Chieti-Pescara, Via dei Vestini 31, 66100 Chieti (CH), Italy; simonetta.dercole@unich.it (S.D.E)

* Correspondence: l.cellini@unich.it Tel.: +39-0871-3554560

Paola Di Fermo and Silvia Di Lodovico contributed equally to this work

Table S1 Antimicrobial susceptibility panel of *H. pylori* clinical strains used in this study

<i>H. pylori</i>	Antimicrobials*								
	CLA	MET	LVX	MOXI	CIP	RIF	TET	AMP	AMOX
11F/11	R	S	R	R	R	S	S	S	S
2A/12	R	R	R	R	R	S	S	S	S
7A/12	S	S	R	R	R	S	S	S	S
12A/12	R	S	R	R	R	S	S	S	S
5A/13	R	R	R	R	R	S	S	S	S
13A/13	R	R	R	R	R	S	S	S	S
26A/13	R	R	R	R	R	S	S	S	S
ATCC 43629	S	S	S	S	S	S	S	S	S

*Abbreviations: CLA, clarithromycin; MET, metronidazole; LVX, levofloxacin; MOXI, moxifloxacin; CIP, ciprofloxacin; RIF, rifabutin; TET, tetracycline; AMP, ampicillin; AMOX, amoxicillin.